Transforming the Treatment of Inflammation and Cancer March 2023 Corporate Presentation Legal Disclaimers Statements in this Presentation that are not statements of historical fact are forward-looking statements. Such forward-looking statements include, without limitation, statements regarding RAPT Therapeutics, Inc.'s (the "Company," "we," or "us") research and clinical development plans; current and future drug candidates; business strategy and plans; regulatory pathways; and our ability to complete certa ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-38997 RAPT THERAPEUTICS, INC. (Exact name of Registrant as specified in its charter) Delaware 47-3313701 (State or other jurisdiction of incorp ...

Transforming the Treatment of Cancer and Inflammation September 2022 Corporate Presentation Legal Disclaimers Statements in this Presentation that are not statements of historical fact are forward-looking statements. Such forward-looking statements include, without limitation, statements regarding RAPT Therapeutics, Inc.'s (the "Company," "we," or "us") research and clinical development plans; current and future drug candidates; business strategy and plans; regulatory pathways; and our ability to complete c ...

Transforming the Treatment of Cancer and Inflammation November 2021 Corporate Presentation Legal Disclaimers Statements in this Presentation that are not statements of historical fact are forward-looking statements. Such forward-looking statements include, without limitation, statements regarding RAPT Therapeutics, Inc.'s (the "Company," "we," or "us") research and clinical development plans; current and future drug candidates; business strategy and plans; regulatory pathways; and our ability to complete ce ...

Transforming the Treatment of Cancer and Inflammation September 2021 Corporate Presentation Legal Disclaimers Statements in this Presentation that are not statements of historical fact are forward-looking statements. Such forward-looking statements include, without limitation, statements regarding RAPT Therapeutics, Inc.'s (the "Company," "we," or "us") research and clinical development plans; current and future drug candidates; business strategy and plans; regulatory pathways; and our ability to complete c ...

Clinical safety and efficacy of RPT193, an oral CCR4 inhibitor: Results from a randomized, placebo-controlled Phase 1b monotherapy trial in patients with moderate-to- severe atopic dermatitis Robert Bissonnette1, Mark Lee2, Janet DuBois3, Joshua Rulloda4, Nadine Lee4, Daniel Johnson4, David Wustrow4, Jasmina Jankicevic4, William Ho4, Laurence Cheng4, Emma Guttman-Yassky5 EADV Late-Breaker Abstract #2746 30 September 2021 1Innovaderm Research Inc., Montreal, Quebec, Canada, 2Progressive Clinical Research, Sa ...

Transforming the Treatment of Cancer and Inflammation May 2021 Corporate Presentation Legal Disclaimers Statements in this Presentation that are not statements of historical fact are forward-looking statements. Such forward-looking statements include, without limitation, statements regarding RAPT Therapeutics, Inc.'s (the "Company," "we," or "us") research and clinical development plans; current and future drug candidates; business strategy and plans; regulatory pathways; and our ability to complete certain ...

Transforming the Treatment of Cancer and Inflammation March 2021 Corporate Presentation Legal Disclaimers Statements in this Presentation that are not statements of historical fact are forward-looking statements. Such forward-looking statements include, without limitation, statements regarding RAPT Therapeutics, Inc.'s (the "Company," "we," or "us") research and clinical development plans; current and future drug candidates; business strategy and plans; regulatory pathways; and our ability to complete certa ...

Transforming the Treatment of Cancer and Inflammation May 2020 Corporate Presentation Legal Disclaimers Statements in this Presentation that are not statements of historical fact are forward-looking statements. Such forward-looking statements include, without limitation, statements regarding RAPT Therapeutics, Inc.'s (the "Company," "we," or "us") research and clinical development plans; current and future drug candidates; business strategy and plans; regulatory pathways; and our ability to complete certain ...

Transforming the Treatment of Cancer and Inflammation March 2020 Corporate Presentation Legal Disclaimers This presentation (the "Presentation") for RAPT Therapeutics, Inc. (the "Company," we," or "our") is made pursuant to Section 5(d) of the Securities Act of 1933 (the "Securities Act"), and is intended solely for investors that are "qualified institutional buyers" (as defined in Rule 144A under the Securities Act) or institutions that are "accredited investors" (as defined in Rule 501 of Regulation D und ...